文献速递神经肿瘤

DNA甲基化亚类可预测IDH野生型胶质母细胞瘤患者从肿瘤全切术中获益

DNA methylation subclasses predict the benefit from gross total tumor resection in IDH-wildtype glioblastoma patients.
PubMed 文献 · Neuro Oncol · 2023-01-01

多中心队列研究纳入430例新诊断胶质母细胞瘤患者行全基因组DNA甲基化分析,345例符合标准。RTK I和RTK II亚类中全切或近全切者总生存和无进展生存优于部分切除者,MES亚类无此获益;MGMT启动子甲基化预测治疗反应见于RTK I和RTK II而非MES。

要点

  • RTK I和RTK II亚类全切或近全切者总生存和无进展生存优于部分切除者
  • MES亚类最大化切除范围未见生存获益(PR vs 全切/近全切 HR 1.45,95%CI 0.68-3.09,p=0.33)
  • MGMT启动子甲基化的治疗反应预测价值见于RTK I和RTK II,MES亚类未达统计学显著

核心结论

  • 新诊断和复发胶质母细胞瘤中,RTK I和RTK II亚类最大化切除范围有生存获益,MES亚类无此获益。
  • 作者认为需讨论MES亚类是否应行最大范围手术切除,尤其位于功能区及复发时。

研究设计与样本

  • 多中心队列研究,纳入430例新诊断胶质母细胞瘤患者行全基因组DNA甲基化分析,345例(80.2%)符合纳入标准,305例接受联合辅助治疗。

主要发现

  • RTK I、RTK II和MES三个DNA甲基化亚类间无显著生存差异(RTK I为参照;RTK II:HR 0.9,95%CI 0.64-1.28,p=0.56;MES:HR 0.69,95%CI 0.47-1.02,p=0.06)。
  • RTK I亚类中部分切除较全切/近全切总生存更差(全切/近全切为参照;PR:HR 2.87,95%CI 1.36-6.08,p<0.01)。
  • RTK II亚类中部分切除较全切/近全切总生存更差(全切/近全切为参照;PR:HR 5.09,95%CI 2.80-9.26,p<0.01)。
  • MES亚类最大化切除范围未见生存获益(全切/近全切为参照;PR:HR 1.45,95%CI 0.68-3.09,p=0.33)。
  • MGMT启动子甲基化的治疗反应预测价值见于RTK I(HR 0.37,95%CI 0.19-0.71,p<0.01)和RTK II(HR 0.56,95%CI 0.34-0.91,p=0.02),MES亚类未达统计学显著(HR 0.52,95%CI 0.27-1.02,p=0.06)。

临床怎么用

  • 作者认为RTK I和RTK II亚类新诊断及复发胶质母细胞瘤可从最大化切除范围中获益。
  • 作者提出需讨论MES亚类是否应行最大范围手术切除,尤其位于功能区及复发时。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: DNA methylation-based tumor classification allows an enhanced distinction into subgroups of glioblastoma. However, the clinical benefit of DNA methylation-based stratification of glioblastomas remains inconclusive. METHODS: Multicentric cohort study including 430 patients with newly diagnosed glioblastoma subjected to global DNA methylation profiling. Outcome measures included overall survival (OS), progression-free survival (PFS), prognostic relevance of EOR and MGMT promoter methylation status as well as a surgical benefit for recurrent glioblastoma. RESULTS: 345 patients (80.2%) fulfilled the inclusion criteria and 305 patients received combined adjuvant therapy. DNA methylation subclasses RTK I, RTK II, and mesenchymal (MES) revealed no significant survival differences (RTK I: Ref.; RTK II: HR 0.9 [95% CI, 0.64-1.28]; p = 0.56; MES: 0.69 [0.47-1.02]; p = 0.06). Patients with RTK I (GTR/near GTR: Ref.; PR: HR 2.87 [95% CI, 1.36-6.08]; p < 0.01) or RTK II (GTR/near GTR: Ref.; PR: HR 5.09 [95% CI, 2.80-9.26]; p < 0.01) tumors who underwent gross-total resection (GTR) or near GTR had a longer OS and PFS than partially resected patients. The MES subclass showed no survival benefit for a maximized EOR (GTR/near GTR: Ref.; PR: HR 1.45 [95% CI, 0.68-3.09]; p = 0.33). Therapy response predictive value of MGMT promoter methylation was evident for RTK I (HR 0.37 [95% CI, 0.19-0.71]; p < 0.01) and RTK II (HR 0.56 [95% CI, 0.34-0.91]; p = 0.02) but not the MES subclass (HR 0.52 [95% CI, 0.27-1.02]; p = 0.06). For local recurrence (n = 112), re-resection conveyed a progression-to-overall survival (POS) benefit (p < 0.01), which was evident in RTK I (p = 0.03) and RTK II (p < 0.01) tumors, but not in MES tumors (p = 0.33). CONCLUSION: We demonstrate a survival benefit from maximized EOR for newly diagnosed and recurrent glioblastomas of the RTK I and RTK II but not the MES subclass. Hence, it needs to be debated whether the MES subclass should be treated with maximal surgical resection, especially when located in eloquent areas and at time of recurrence.

来源:Neuro Oncol,查看原文。版权归原作者所有。

引用

  1. Drexler R, Schüller U, Eckhardt A, et al. DNA methylation subclasses predict the benefit from gross total tumor resection in IDH-wildtype glioblastoma patients. Neuro Oncol. 2023. PMID: 35868257. doi:10.1093/neuonc/noac177

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。